Eisai R&d Management Co., Ltd.

Merck Sharp + Dohme Corp.

Eisai Company, Limited

Kimiyo Tabata

Richard S Clark

Tadashi Nagakura

Fumiyoshi Matsuura

Kazunobu Kira

Atsushi Inoue

Hiroshi Azuma

Shinsuke Hirota

Tatsuo Horizoe

Takao Omae

Kazutomi Kusano

Andrew Evan Denker

Yusaku Hori

Yu Kato

Osamu Asano

Nobuhisa Watanabe

Atsushi Takemura

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein Ris Calkyl or Ccycloalkyl, Ris a hydrogen atom or Calkoxy, and Ris a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): 

Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer

A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R, R, Rand Reach independently represent hydrogen, etc.; Rrepresents optionally substituted phenyl, etc.; Rrepresents optionally substituted C6-10 aryl, etc.; and Zand Zeach independently represent hydrogen.

Triazolone derivatives

A Compound represented by the following general formula (1): wherein R, R, Rand Reach independently represent hydrogen, etc.; Rrepresents optionally substituted phenyl, etc.; Rrepresents optionally substituted C6-10 aryl, etc.; and Zand Zeach independently represent hydrogen or salts thereof or hydrates of the foregoing.

A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R, R, Rand Reach independently represent hydrogen, etc.; Rrepresents optionally substituted phenyl, etc.; Rrepresents optionally substituted C6-10 aryl, etc.; and Zand Zeach independently represent hydrogen]

A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation. [wherein Rrepresents hydrogen, Rrepresents optionally substituted phenyl, etc., Rrepresents optionally substituted C6-10 aryl, etc.].

2,3-dihydro-iminoisoindole derivatives

Growing community of inventors

Tsukuba, Japan

Kimiyo Tabata